Champions Oncology, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended April 30, 2023; comparisons are with the year ended April 30, 2022. The filing is an annual report, not a standalone fourth-quarter report.
Business context
Champions provides oncology research services to pharmaceutical and biotechnology companies using patient-derived xenograft (PDX) models, experimental platforms, and data analytics. Its businesses include Translational Oncology Solutions research services, the Lumin Bioinformatics SaaS platform, and early-stage drug discovery and development. Research services are the primary revenue source; the company reports one operating segment.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $53.9 million | $49.1 million |
| Gross profit / margin | $24.3 million / 45% | $25.5 million / 52% |
| Operating income (loss) | $(5.3) million | $0.6 million |
| Net income (loss) | $(5.3) million | $0.5 million |
| Diluted earnings (loss) per share | $(0.39) | $0.04 |
| Cash provided by operating activities | $4.0 million | $6.5 million |
| Cash used in investing activities | $2.9 million | $2.4 million |
| Cash and cash equivalents at year-end | $10.1 million | $9.0 million |
| Working capital | $(2.3) million | Not stated here |
| Total liabilities | $29.7 million | $26.3 million |
Revenue grew 9.7%, while cost of oncology services rose 25.0% to $29.5 million. Research and development expense increased 23.2% to $11.5 million; sales and marketing rose 9.8% to $7.0 million; and general and administrative expense rose 12.3% to $10.2 million. The filing reports no off-balance-sheet debt or similar obligations. Balance-sheet liabilities include $8.6 million of operating lease liabilities; the company also discloses finance leases for laboratory equipment.
Material changes and unusual items
- Pharmacology services revenue increased to $50.7 million from $46.8 million. Other TOS revenue was $3.0 million, including flow cytometry and SaaS; personalized oncology services revenue was $116,000.
- Management attributed revenue growth to expanded platforms and larger in-vivo and ex-vivo studies. Gross margin declined seven percentage points, which management attributed to compensation and supply costs rising to support revenue growth that did not materialize as expected.
- The company recorded an $807,000 impairment charge for Lumin software development costs in FY2023 after weaker revenue growth and slower new bookings led management to conclude the carrying value was not recoverable. Lumin’s net book value was reduced to zero.
- Operating cash flow fell by $2.5 million year over year, primarily in connection with the net loss. FY2023 cash generation also reflected working-capital movements, including increased deferred revenue.
- The board authorized up to $5.0 million in share repurchases in March 2023. By year-end, the company had repurchased 14,422 shares for approximately $74,000.
Outlook, risks, and contingencies
Management believes cash on hand and expected operating cash flows are sufficient to fund operations through at least August 2024, despite negative working capital and the annual net loss. The filing gives no specific revenue, earnings, or margin guidance. Management is continuing investment in research platforms and drug discovery, and says it regularly evaluates strategic options for that business, potentially including a spin-out or capital raise.
- Profitability is uncertain: the company has an accumulated deficit of $77.3 million and warns it may need additional capital; financing may not be available on acceptable terms.
- Revenue depends heavily on customer research programs, which can be modified or cancelled. One customer represented 14% of revenue in FY2023 and 14% of year-end accounts receivable.
- Key operating risks include intense competition, dependence on skilled personnel, regulatory and laboratory requirements, protection of unpatented know-how, and potential disruption to laboratory facilities or the mouse colony.
- Cybersecurity, public-health events, inflation and economic conditions could disrupt operations or reduce customer research spending. The company said it had experienced cyber threats but was not aware of a material breach.
- Deferred tax assets are fully offset by a valuation allowance. Management also identifies potential limits on use of net operating losses following ownership changes.
- No legal proceedings were reported. The auditor issued an unmodified opinion on the financial statements and identified revenue recognition and deferred revenue estimates as a critical audit matter. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not express an opinion on internal controls.
Most important facts for investors to verify
- Whether revenue growth can recover sufficiently to absorb higher service costs and restore gross margin.
- Whether Lumin bookings and revenue improve, and whether additional investment is justified after the impairment.
- Whether cash flow supports operations through the stated August 2024 horizon, particularly given negative working capital and ongoing research investment.
- Customer concentration, deferred revenue, project progress estimates, and the collectability of receivables; revenue recognition was the auditor’s critical audit matter.
- Potential dilution or capital needs, including the extent of future share repurchases and any financing or strategic transactions.